AIMS: Exposure to human adenovirus Ad36 is causatively and correlatively linked with better glycemic control in animals and humans, respectively. Although the anti-hyperglycemic property of Ad36 may offer some therapeutic potential, it is impractical to use an infectious agent for therapeutic benefit. Cell-based studies identified that Ad36 enhances cellular glucose disposal via its E4orf1 protein. Ability to improve glycemic control in vivo is a critical prerequisite for further investigating the therapeutic potential of E4orf1. Therefore, the aim of this study was to determine the ability of E4orf1 to improve glycemic control independent of insulin despite high fat diet. MATERIALS & METHODS: 8-9wk old male C57BL/6J mice fed a high-fat diet (60% kcal) were injected with a retrovirus plasmid expressing E4orf1, or a null vector (Control). Glycemic control was determined by glucose and insulin tolerance test. Islet cell size, amount of insulin and glucagon were determined in formalin-fixed pancreas. Rat insulinoma cell line (832/13) was infected with E4orf1 or control to determine changes in glucose stimulated insulin secretion. Protein from flash frozen adipose tissue depots, liver and muscle was used to determine molecular signaling by western blotting. RESULTS: In multiple experiments, retrovirus-mediated E4orf1 expression in C57BL/6J mice significantly and reproducibly improved glucose excursion following a glucose load despite a high fat diet (60% energy). Importantly, E4orf1 improved glucose clearance without increasing insulin sensitivity, production or secretion, underscoring its insulin-independent effect. E4orf1 modulated molecular signaling in mice tissue, which included greater protein abundance of adiponectin, p-AKT and Glucose transporter Glu4. CONCLUSIONS: This study provides the proof of concept for translational development of E4orf1 as a potential anti-diabetic agent. High fat intake and impaired insulin signaling are often associated with obesity, diabetes and insulin resistance. Hence, the ability of E4orf1 to improve glycemic control despite high fat diet and independent of insulin, is particularly attractive.
AIMS: Exposure to human adenovirus Ad36 is causatively and correlatively linked with better glycemic control in animals and humans, respectively. Although the anti-hyperglycemic property of Ad36 may offer some therapeutic potential, it is impractical to use an infectious agent for therapeutic benefit. Cell-based studies identified that Ad36 enhances cellular glucose disposal via its E4orf1 protein. Ability to improve glycemic control in vivo is a critical prerequisite for further investigating the therapeutic potential of E4orf1. Therefore, the aim of this study was to determine the ability of E4orf1 to improve glycemic control independent of insulin despite high fat diet. MATERIALS & METHODS: 8-9wk old male C57BL/6J mice fed a high-fat diet (60% kcal) were injected with a retrovirus plasmid expressing E4orf1, or a null vector (Control). Glycemic control was determined by glucose and insulin tolerance test. Islet cell size, amount of insulin and glucagon were determined in formalin-fixed pancreas. Rat insulinoma cell line (832/13) was infected with E4orf1 or control to determine changes in glucose stimulated insulin secretion. Protein from flash frozen adipose tissue depots, liver and muscle was used to determine molecular signaling by western blotting. RESULTS: In multiple experiments, retrovirus-mediated E4orf1 expression in C57BL/6J mice significantly and reproducibly improved glucose excursion following a glucose load despite a high fat diet (60% energy). Importantly, E4orf1 improved glucose clearance without increasing insulin sensitivity, production or secretion, underscoring its insulin-independent effect. E4orf1 modulated molecular signaling in mice tissue, which included greater protein abundance of adiponectin, p-AKT and Glucose transporter Glu4. CONCLUSIONS: This study provides the proof of concept for translational development of E4orf1 as a potential anti-diabetic agent. High fat intake and impaired insulin signaling are often associated with obesity, diabetes and insulin resistance. Hence, the ability of E4orf1 to improve glycemic control despite high fat diet and independent of insulin, is particularly attractive.
Authors: R L Atkinson; N V Dhurandhar; D B Allison; R L Bowen; B A Israel; J B Albu; A S Augustus Journal: Int J Obes (Lond) Date: 2005-03 Impact factor: 5.095
Authors: P M Rogers; K A Fusinski; M A Rathod; S A Loiler; M Pasarica; M K Shaw; G Kilroy; G M Sutton; E J McAllister; N Mashtalir; J M Gimble; T C Holland; N V Dhurandhar Journal: Int J Obes (Lond) Date: 2007-11-06 Impact factor: 5.095
Authors: Nikhil V Dhurandhar; Leah D Whigham; David H Abbott; Nancy J Schultz-Darken; Barbara A Israel; Steven M Bradley; Joseph W Kemnitz; David B Allison; Richard L Atkinson Journal: J Nutr Date: 2002-10 Impact factor: 4.798
Authors: I Aldhoon-Hainerová; H Zamrazilová; R L Atkinson; L Dušátková; B Sedláčková; P Hlavatý; Z P Lee; M Kunešová; V Hainer Journal: Int J Obes (Lond) Date: 2013-05-14 Impact factor: 5.095
Authors: Malin Almgren; Richard Atkinson; Jia He; Agneta Hilding; Emilia Hagman; Alicja Wolk; Anders Thorell; Claude Marcus; Erik Näslund; Claes-Göran Östenson; Martin Schalling; Catharina Lavebratt Journal: PLoS One Date: 2012-07-27 Impact factor: 3.240
Authors: N V Dhurandhar; L Geurts; R L Atkinson; L Casteilla; K Clement; P Gerard; M Vijay-Kumar; J H Nam; M Nieuwdorp; G Trovato; T I A Sørensen; A Vidal-Puig; P D Cani Journal: Obes Rev Date: 2013-05-12 Impact factor: 9.213